Gilead ( GILD) was a leading biotech in the fight against HIV, posting tremendous annual growth in sales and profits. Sales grew at least 26% every year last decade. Yet this former highflyer has surely matured as sales are growing in the high single-digits these days. But sales and profit growth rates could move back into the low teens by the middle of the decade thanks to a robust pipeline of cardio-pulmonary drugs. Gilead's HIV franchise also has plenty of life left in it as key drugs get tweaked to boost efficacy. Gilead, one of SAC Capital's holdings, shows up on a list of 10 Stocks Owned by the Best Fund Managers.